Human PD-L1/B7-H1 Protein

产品信息(Product Info)

Recombinant Human PD-L1/B7-H1 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Phe19-Arg238.[Accession | Q9NZQ7-1]

分子量大小(Molecular Weight)

The protein has a predicted MW of 26 kDa. Due to glycosylation, the protein migrates to 35-42 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.


Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.


-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Human PD-L1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.


The purity of Human PD-L1 is greater than 95% as determined by SEC-HPLC.


Immobilized Human PD-L1, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-PD-L1 Antibody, hFc Tag with the EC50 of 6.4ng/ml determined by ELISA.

37℃ Stability Test

Immobilized Human PD-L1, His Tag at 0.5μg/ml (100μl/Well). Dose response curve for Anti-PD-L1 Ab., hFc Tag with the EC50 of 6.4/6.4/6.5/6.6ng/ml determined by ELISA.


B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance.


CD274; PDL1; PD-L1; PD-L1B7 homolog 1;B7-H; B7H1; B7-H1; PDCD1L1; PDCD1LG1


(1)Blank C , Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion[J]. Cancer Immunology Immunotherapy, 2007, 56(5):739-745.